Syon Capital LLC Takes $313,000 Position in Exelixis, Inc. (NASDAQ:EXEL)

Syon Capital LLC acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 9,403 shares of the biotechnology company's stock, valued at approximately $313,000.

Several other large investors have also bought and sold shares of the business. Vanguard Group Inc. increased its stake in Exelixis by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 29,429,252 shares of the biotechnology company's stock valued at $979,994,000 after purchasing an additional 121,750 shares in the last quarter. LSV Asset Management increased its stake in Exelixis by 0.8% in the fourth quarter. LSV Asset Management now owns 8,169,847 shares of the biotechnology company's stock valued at $272,056,000 after purchasing an additional 67,470 shares in the last quarter. Fuller & Thaler Asset Management Inc. increased its stake in Exelixis by 10.2% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 7,630,940 shares of the biotechnology company's stock valued at $254,110,000 after purchasing an additional 708,312 shares in the last quarter. Invesco Ltd. increased its stake in Exelixis by 308.1% in the fourth quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company's stock valued at $132,376,000 after purchasing an additional 3,001,204 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its stake in Exelixis by 104.4% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 3,159,395 shares of the biotechnology company's stock valued at $105,208,000 after purchasing an additional 1,613,482 shares in the last quarter. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Exelixis Price Performance

EXEL stock traded down $0.24 during trading hours on Thursday, reaching $38.91. The stock had a trading volume of 724,258 shares, compared to its average volume of 2,176,925. The stock has a market capitalization of $10.72 billion, a PE ratio of 21.99, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. The stock has a 50-day simple moving average of $36.86 and a 200 day simple moving average of $34.87. Exelixis, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $40.02.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, sell-side analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Insider Transactions at Exelixis

In other news, Director Jack L. Wyszomierski sold 8,768 shares of the business's stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $37.80, for a total transaction of $331,430.40. Following the completion of the sale, the director now owns 356,605 shares in the company, valued at $13,479,669. The trade was a 2.40 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Patrick J. Haley sold 52,636 shares of the business's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $36.98, for a total value of $1,946,479.28. Following the sale, the executive vice president now owns 303,310 shares of the company's stock, valued at approximately $11,216,403.80. This represents a 14.79 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 140,343 shares of company stock worth $5,177,234 over the last quarter. Company insiders own 2.85% of the company's stock.

Analyst Ratings Changes

Several brokerages have commented on EXEL. Piper Sandler upped their target price on shares of Exelixis from $37.00 to $38.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. Barclays increased their price objective on shares of Exelixis from $25.00 to $29.00 and gave the stock an "equal weight" rating in a research report on Thursday, February 13th. Stephens reissued an "equal weight" rating and set a $29.00 price objective on shares of Exelixis in a research report on Wednesday, February 12th. HC Wainwright reissued a "buy" rating and set a $40.00 price objective on shares of Exelixis in a research report on Thursday, March 27th. Finally, JMP Securities reissued a "market outperform" rating and set a $41.00 price objective on shares of Exelixis in a research report on Thursday, April 17th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $37.59.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.